Scott Shively
- Role
- President & CEO at Bexion Pharmaceuticals
- Location
- Morristown, NJ, US
- LinkedIn followers
- 500 followers
About Scott Shively
Scott is an experienced executive leader in the US and international pharmaceutical…
Experience
President & CEO
Feb 2022 — Present
Bexion Pharmaceuticals is a clinical-stage biopharmaceutical company developing a new generation of biologic immunotherapy. The lead drug candidate, BXQ-350 modulates lysosomal sphingolipid metabolism, inducing tumor cell death and imparting both innate and adaptive immune activity. Bexion’s lead drug candidate is BXQ-350 is a first-in-class biologic containing the multifunctional, lysosomal activator protein, Saposin C in a nanovesicle formulation to treat cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN).
Education
Duke University
Bachelor of Science (B.S.), Zoology
Duke University
Bachelor’s Degree, Zoology, Chemistry
1976 — 1979
Skills
- Managed Care
- Strategic Planning
- Supply Chain
- Leadership
- Integrated Medicine
- Sales Effectiveness
- Clinical Trials
- Lifesciences
- Sales
- Revenue & Profit Growth
- Cross-Functional Team Leadership
- Pharmaceutical Sales
- Business Development
- Sales Operations
- Management
- Medical Devices
- Clinical Development
- Marketing
- Product Launch
- Biotechnology
- Commercialization
- Neurology
- Mergers & Acquisitions
- Fda
- Business Strategy
- Pain Management
- Accountability
- Biopharmaceuticals
- Strategy
- Healthcare
- Growth Strategies
- Pharmaceutical Industry
- Life Sciences
- Global Marketing
- New Product Launches
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.